NASDAQ:TTNP Titan Pharmaceuticals (TTNP) Stock Forecast, Price & News $0.78 +0.01 (+1.31%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$0.75▼$0.7850-Day Range$0.73▼$0.8352-Week Range$0.39▼$1.59Volume11,138 shsAverage Volume21,068 shsMarket Capitalization$11.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Titan Pharmaceuticals (NASDAQ:TTNP) StockTitan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.Read More Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TTNP Stock News HeadlinesJune 1, 2023 | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.comMay 26, 2023 | finance.yahoo.comTTNP - Titan Pharmaceuticals, Inc.June 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 25, 2023 | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.comMay 23, 2023 | sports.yahoo.comWatch: Prowling tiger bows to ‘titan herd’ of elephantsMay 17, 2023 | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.comMay 1, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)April 30, 2023 | americanbankingnews.comTitan Pharmaceuticals, Inc. (NASDAQ:TTNP) Sees Large Increase in Short InterestJune 1, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.April 22, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)March 22, 2023 | seekingalpha.comTTNP Titan Pharmaceuticals, Inc.March 21, 2023 | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated by Analysts at StockNews.comDecember 15, 2022 | finance.yahoo.comTitan Pharmaceuticals Provides Shareholder UpdateDecember 12, 2022 | nz.finance.yahoo.comTitan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.November 21, 2022 | bizjournals.comChapel Hill surgical tech company shapes plan to keep Nasdaq listingNovember 17, 2022 | finance.yahoo.comTitan Pharmaceuticals Third Quarter 2022 Earnings: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021)November 4, 2022 | msn.comTitan, GAIL, TVS Motor, Britannia & Other Stocks to Release Q2 Results TodayAugust 17, 2022 | benzinga.comTitan Pharmaceuticals Announces Board Expansion...August 16, 2022 | finance.yahoo.comTitan Pharmaceuticals Announces Board Expansion and Management ChangesJuly 11, 2022 | insidermonkey.comHedge Fund and Insider Trading News: George Soros, Jim Simons, Three Arrows Capital, Rocket Companies Inc (RKT), Titan Pharmaceuticals, Inc. (TTNP), and MoreJuly 11, 2022 | finance.yahoo.comActivist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of StockholdersJuly 9, 2022 | finance.yahoo.comHere's Why We're Watching Titan Pharmaceuticals' (NASDAQ:TTNP) Cash Burn SituationJuly 6, 2022 | benzinga.comTitan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder StudyJuly 5, 2022 | nasdaq.comTitan Pharma Says FDA Clears IND Application For Nalmefene ImplantJuly 5, 2022 | finance.yahoo.comTitan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene ImplantJune 10, 2022 | finance.yahoo.comActivist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.April 25, 2022 | apnews.comActivist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.See More Headlines TTNP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTNP Company Calendar Last Earnings3/30/2021Today6/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTNP CUSIPN/A CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees11Year Founded1992Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,210,000.00 Net Margins-2,017.49% Pretax Margin-2,017.49% Return on Equity-363.89% Return on Assets-179.45% Debt Debt-to-Equity RatioN/A Current Ratio0.73 Quick Ratio0.69 Sales & Book Value Annual Sales$560,000.00 Price / Sales20.44 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-38.10Miscellaneous Outstanding Shares15,020,000Free Float10,827,000Market Cap$11.45 million OptionableOptionable Beta1.10 Social Links Key ExecutivesDavid Elliot LazarChairman, Chief Executive & Financial OfficerKatherine L. Beebe-DeVarneyPresident, Chief Operating Officer & DirectorBrian E. CrowleyVice President-FinanceKey CompetitorsFreeline TherapeuticsNASDAQ:FRLNAceragenNASDAQ:ACGNTRACON PharmaceuticalsNASDAQ:TCONFinch Therapeutics GroupNASDAQ:FNCHPalisade BioNASDAQ:PALIView All CompetitorsInsidersDavid E LazarBought 37,500 shares on 1/24/2023Total: $36,375.00 ($0.97/share)David E LazarBought 1,165,975 shares on 7/6/2022Total: $897,800.75 ($0.77/share)View All Insider Transactions TTNP Stock - Frequently Asked Questions How have TTNP shares performed in 2023? Titan Pharmaceuticals' stock was trading at $0.7831 on January 1st, 2023. Since then, TTNP stock has decreased by 2.7% and is now trading at $0.7620. View the best growth stocks for 2023 here. Are investors shorting Titan Pharmaceuticals? Titan Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 46,200 shares, a decline of 26.1% from the April 30th total of 62,500 shares. Based on an average daily trading volume, of 15,000 shares, the days-to-cover ratio is presently 3.1 days. View Titan Pharmaceuticals' Short Interest. How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) released its quarterly earnings data on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.47. Titan Pharmaceuticals had a negative trailing twelve-month return on equity of 363.89% and a negative net margin of 2,017.49%. When did Titan Pharmaceuticals' stock split? Shares of Titan Pharmaceuticals reverse split on the morning of Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI). What is Titan Pharmaceuticals' stock symbol? Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP." How do I buy shares of Titan Pharmaceuticals? Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Titan Pharmaceuticals' stock price today? One share of TTNP stock can currently be purchased for approximately $0.76. How much money does Titan Pharmaceuticals make? Titan Pharmaceuticals (NASDAQ:TTNP) has a market capitalization of $11.45 million and generates $560,000.00 in revenue each year. How can I contact Titan Pharmaceuticals? Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The official website for the company is www.titanpharm.com. The specialty pharmaceutical company can be reached via phone at (650) 244-4990, via email at skilmer@titanpharm.com, or via fax at 650-244-4956. This page (NASDAQ:TTNP) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.